4/A: Protalix BioTherapeutics CFO Amends SEC Filing to Correct Stock Grant Reporting

Eyal Rubin, CFO of Protalix BioTherapeutics, files an amended SEC Form 4 to correct a previously reported amount of restricted shares granted.

Summary

• Eyal Rubin, the Senior VP and CFO of Protalix BioTherapeutics, Inc., filed an amendment to a previous Form 4 with the SEC.
• The amendment, filed on November 5, 2024, corrects an administrative error in the original filing from September 24, 2024.
• The error involved misreporting the amount of restricted shares granted to Rubin.
• The corrected filing shows Rubin beneficially owns 660,909 shares indirectly through a trust and 90,909 shares directly.
• These shares were awarded under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan.

Sentiment

Score: 7

Explanation: The document is a routine correction of an administrative error in an SEC filing. It doesn't indicate any fundamental change in the company's financial health or prospects, but transparency is generally viewed positively.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency in the market.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders and potential investors.

Key Dates